Future Health Research

1 in 10 people worldwide live with Chronic Kidney Disease (CKD), but fewer than 10% are diagnosed. Metabolic Dysfunction-Associated Steatohepatitis (MASH) — a serious form of fatty liver disease — is similarly under-detected, with fewer than 5% of those at-risk identified. Both conditions are progressive, increasingly treatable when caught early, and sit at the heart of the rising global burden of cardiovascular-renal-metabolic disease. In Geneva this week for the World Health Assembly, Future Health Research is launching a new draft global policy roadmap on improving the earlier screening and diagnosis of CKD and MASH. The draft roadmap is designed to help governments translate two important global commitments into action: the 2025 WHO resolution on kidney health, and the UN political declaration on NCDs which for the first time explicitly commits signatories to strengthening screening and management for CKD and liver disease. The draft roadmap sets out five practical pillars countries can use — awareness, risk stratification, screening, integrated care, and evaluation — with case studies drawn from around the world. This is a draft. Future Health Research is now consulting on the recommendations, with a final Roadmap for use by country and regional-level policy makers due later in 2026. We would very much welcome feedback from healthcare professionals, patient organisations, payers and policymakers. This draft roadmap was commissioned and funded by Boehringer Ingelheim; full editorial control rests with Future Health. This is part of a growing global health policy programme at Future Health Research, building on The power of connection: Strengthening health policy responses to cardiovascular, renal and metabolic diseases (launched at WHA 2025). If you'd like to discuss or find out more then please do get in touch. Read more here: https://lnkd.in/eKrrGff4 #WHA79 #CKD #MASH #MASLD #NCDs #GlobalHealth

Pulmonary Fibrosis (PF) is a devastating, progressive scarring of the lungs for which there is currently no cure. Its most prevalent form — Idiopathic Pulmonary Fibrosis — affects more than 3 million people worldwide, with a median survival of just 2.5 to 5 years after diagnosis, comparable to and in some cases worse than many cancers. In Geneva this week for the World Health Assembly (WHA), we are launching Breathing new life into lung health policy — a new global research report on how governments and policymakers can use the World Health Organisation’s (WHO) Lung Health Resolution to improve outcomes for people with PF. The adoption of the Lung Health Resolution at WHA78 last year was the most significant advance in global lung health governance in a generation, and the first time PF has been included in a global health resolution. The challenge now is translating such commitments into action. The report sets out a four-part framework of recommendations aimed at delivering on the ambitions of the Lung Health Resolution and wider global health commitments on reducing mortality from non-communicable diseases: enhancing prevention and increasing awareness; earlier diagnosis; integrated care; investment in research and improving access to new treatments. It draws on an extensive evidence review and consultation with experts, clinicians and patient organisations across the world. Thank you to everyone who contributed – particularly Steve Jones and the other experts who formed our initial expert group meeting late last year. This research was commissioned and funded by Boehringer Ingelheim; full editorial control rests with Future Health. This is part of a growing global health policy programme at Future Health Research. Do get in touch if you'd like to discuss our work, or how we might support yours. Read our report here: https://lnkd.in/ecu_UyNj #WHA79 #LungHealth #PulmonaryFibrosis #GlobalHealth #NCDs